Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016

MMWR Surveillance Summaries

Volumn 68, Issue 8, 2019, Pages 1-17

  Toda, Mitsuru ^a,b   Williams, Sabrina R ^b   Berkow, Elizabeth L ^b   Farley, Monica M ^c   Harrison, Lee H ^d   Bonner, Lindsay ^d   Marceaux, Kaytlynn M ^d   Hollick, Rosemary ^d   Zhang, Alexia Y ^e   Schaffner, William ^f   Lockhart, Shawn R ^b   Jackson, Brendan R ^b   Vallabhaneni, Snigdha ^b  

^a Epidemiology and Laboratory Services   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e OREGON HEALTH AUTHORITY   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANCESTRY GROUP; CANDIDA; CANDIDEMIA; CHILD; CULTURE MEDIUM; ETHNOLOGY; FEMALE; HEALTH SURVEY; HUMAN; INFANT; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; PRESCHOOL CHILD; PROCEDURES; SEX RATIO; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CANDIDA; CANDIDEMIA; CHILD; CHILD, PRESCHOOL; CONTINENTAL POPULATION GROUPS; CULTURE MEDIA; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; SEX DISTRIBUTION; UNITED STATES; YOUNG ADULT;

EID: 85072700887     PISSN: 15460738     EISSN: 15458636     Source Type: Journal    
DOI: 10.15585/mmwr.ss6808a1     Document Type: Article

References (71)

1. 1. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133–63. https://doi.org/10.1128/CMR.00029-06
2. 2. Vallabhaneni S, Mody RK, Walker T, Chiller T. The global burden of fungal diseases. Infect Dis Clin North Am 2016;30:1–11. https://doi. org/10.1016/j.idc.2015.10.004
3. 3. Magill SS, O’Leary E, Janelle SJ, et al; Emerging Infections Program Hospital Prevalence Survey Team. Changes in prevalence of health careassociated infections in U.S. hospitals. N Engl J Med 2018;379:1732–44. https://doi.org/10.1056/NEJMoa1801550
4. 4. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in U.S. hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309–17. https://doi.org/10.1086/421946
5. 5. Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol 2016;37:1288–301. https://doi.org/10.1017/ice.2016.174
6. 6. Cleveland AA, Farley MM, Harrison LH, et al. Changes in incidence and antifungal drug resistance in candidemia: results from populationbased laboratory surveillance in Atlanta and Baltimore, 2008–2011. Clin Infect Dis 2012;55:1352–61. https://doi.org/10.1093/cid/cis697
7. 7. Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis 2001;33:1959–67. https://doi.org/10.1086/323759
8. 8. Sims CR, Ostrosky-Zeichner L, Rex JH. Invasive candidiasis in immunocompromised hospitalized patients. Arch Med Res 2005;36:660–71. https://doi.org/10.1016/j.arcmed.2005.05.015
9. 9. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989;149:2349–53. https://doi.org/10.1001/ archinte.1989.00390100145030
10. 10. Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med 2015;373:1445–56. https://doi.org/10.1056/NEJMra1315399
11. 11. Pammi M, Holland L, Butler G, Gacser A, Bliss JM. Candida parapsilosis is a significant neonatal pathogen: a systematic review and meta-analysis. Pediatr Infect Dis J 2013;32:e206–16. https://doi.org/10.1097/ INF.0b013e3182863a1c
12. 12. Feja KN, Wu F, Roberts K, et al. Risk factors for candidemia in critically ill infants: a matched case-control study. J Pediatr 2005;147:156–61. https://doi.org/10.1016/j.jpeds.2005.02.021
13. 13. Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers 2018;4:18026. https://doi.org/10.1038/nrdp.2018.26
14. 14. Schelenz S, Hagen F, Rhodes JL, et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control 2016;5:35. https://doi.org/10.1186/ s13756-016-0132-5
15. 15. Segal BH, Almyroudis NG, Battiwalla M, et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007;44:402–9. https://doi.org/10.1086/510677
16. 16. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001;345:1660–6. https://doi. org/10.1056/NEJMoa010494
17. 17. Lockhart SR, Iqbal N, Cleveland AA, et al. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. J Clin Microbiol 2012;50:3435–42. https://doi.org/10.1128/JCM.01283-12
18. 18. Dimopoulos G, Ntziora F, Rachiotis G, Armaganidis A, Falagas ME. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg 2008;106:523–9. https://doi.org/10.1213/ane.0b013e3181607262
19. 19. Vallabhaneni S, Cleveland AA, Farley MM, et al. Epidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstream infections: data from a large multisite population-based candidemia surveillance program, 2008–2014. Open Forum Infect Dis 2015;2:ofv163.
20. 20. Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013;56:1724–32. https://doi.org/10.1093/cid/cit136
21. 21. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. nov., a novel Ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol 2009;53:41–4. https://doi.org/10.1111/j.1348-0421.2008.00083.x
22. 22. CDC. Tracking Candida auris [Internet]. Atlanta, GA: US Department of Health and Human Services, CDC; 2018. https://www.cdc.gov/fungal/ diseases/candidiasis/tracking-c-auris.html
23. 23. Banerjee SN, Emori TG, Culver DH, et al; National Nosocomial Infections Surveillance System. Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989. Am J Med 1991;91(3B):86S–9S. https://doi.org/10.1016/0002-9343(91)90349-3
24. 24. Gaynes RP, Culver DH, Emori TG, et al. The national nosocomial infections surveillance system: plans for the 1990s and beyond. Am J Med 1991;91(3B):116S–20S. https://doi.org/10.1016/0002-9343(91)90355-2
25. 25. Fridkin SK, Kaufman D, Edwards JR, Shetty S, Horan T. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995–2004. Pediatrics 2006;117:1680–7. https:// doi.org/10.1542/peds.2005-1996
26. 26. Benedict K, Roy M, Kabbani S, et al. Neonatal and pediatric candidemia: results from population-based active laboratory surveillance in four U.S. locations, 2009–2015. J Pediatric Infect Dis Soc 2018;7:e78–85 https:// doi.org/10.1093/jpids/piy009.
27. 27. Fisher BT, Ross RK, Localio AR, Prasad PA, Zaoutis TE. Decreasing rates of invasive candidiasis in pediatric hospitals across the United States. Clin Infect Dis 2014;58:74–7. https://doi.org/10.1093/cid/cit679
28. 28. Cleveland AA, Harrison LH, Farley MM, et al. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two U.S. metropolitan areas, 2008–2013: results from population-based surveillance. PLoS One 2015;10:e0120452. https://doi.org/10.1371/ journal.pone.0120452
29. 29. Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999;29:1164–70. https://doi.org/10.1086/313450
30. 30. Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004;42:1519–27. https://doi.org/10.1128/ JCM.42.4.1519-1527.2004
31. 31. CDC. Candida auris. 2019 case definition [Internet]. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. https://wwwn. cdc.gov/nndss/conditions/candida-auris/case-definition/2019
32. 32. CDC. Emerging Infections Program [Internet]. Atlanta, GA: US Department of Health and Human Services, CDC; 2018. https://www. cdc.gov/ncezid/dpei/eip/index.html
33. 33. Deak E, Etienne KA, Lockhart SR, Gade L, Chiller T, Balajee SA. Utility of a Luminex-based assay for multiplexed, rapid species identification of Candida isolates from an ongoing candidemia surveillance. Can J Microbiol 2010;56:348–51. https://doi.org/10.1139/W10-003
34. 34. Hillenkamp F, Karas M, Beavis RC, Chait BT. Matrix-assisted laser desorption/ionization mass spectrometry of biopolymers. Anal Chem 1991;63:1193A–203A. https://doi.org/10.1021/ac00024a716
35. 35. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard—third edition [Internet]. CLSI document no. M27–A3. Vol. 27, No. 9. Wayne, PA: Clinical and Laboratory Standards Institute; 2008. https://clsi.org/media/1461/m27a3_sample.pdf
36. 36. Pfaller MA, Espinel-Ingroff A, Canton E, et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol 2012;50:2040–6. https://doi. org/10.1128/JCM.00248-12
37. 37. US Census Bureau. Population and housing unit estimates data. Washington, DC: US Census Bureau; 2018. https://www.census.gov/ programs-surveys/popest/data.html
38. 38. Freedman M, Jackson BR, McCotter O, Benedict K. Coccidioidomycosis outbreaks, United States and worldwide, 1940–2015. Emerg Infect Dis 2018;24:417–23. https://doi.org/10.3201/eid2403.170623
39. 39. Armstrong PA, Jackson BR, Haselow D, et al. Multistate epidemiology of histoplasmosis, United States, 2011–2014. Emerg Infect Dis 2018;24:425–31. https://doi.org/10.3201/eid2403.171258
40. 40. Mokdad AH, Ballestros K, Echko M, et al; US Burden of Disease Collaborators. The state of U.S. health, 1990–2016: burden of diseases, injuries, and risk factors among U.S. states. JAMA 2018;319:1444–72. https://doi.org/10.1001/jama.2018.0158
41. 41. Murray CJL, Kulkarni SC, Michaud C, et al. Eight Americas: investigating mortality disparities across races, counties, and racecounties in the United States. PLoS Med 2006;3:e260. https://doi. org/10.1371/journal.pmed.0030260
42. 42. Sanchez GV, Fleming-Dutra KE, Roberts RM, Hicks LA. Core elements of outpatient antibiotic stewardship. MMWR Recomm Rep 2016;65(No. RR-6). https://doi.org/10.15585/mmwr.rr6506a1
43. 43. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62:e1–e50. https:// doi.org/10.1093/cid/civ1194
44. 44. Waters TM, Daniels MJ, Bazzoli GJ, et al. Effect of Medicare’s nonpayment for hospital-acquired conditions: lessons for future policy. JAMA Intern Med 2015;175:347–54. https://doi.org/10.1001/ jamainternmed.2014.5486
45. 45. Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother 2018;73(suppl_1):i4–13. https://doi.org/10.1093/jac/dkx444
46. 46. Restrepo A, Salazar ME, Cano LE, Stover EP, Feldman D, Stevens DA. Estrogens inhibit mycelium-to-yeast transformation in the fungus Paracoccidioides brasiliensis: implications for resistance of females to paracoccidioidomycosis. Infect Immun 1984;46:346–53.
47. 47. Salazar ME, Restrepo A, Stevens DA. Inhibition by estrogens of conidium-to-yeast conversion in the fungus Paracoccidioides brasiliensis. Infect Immun 1988;56:711–3.
48. 48. Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992–1993: results of population-based laboratory active surveillance. Clin Infect Dis 1998;27:1138–47. https://doi. org/10.1093/clinids/27.5.1138
49. 49. Strollo S, Lionakis MS, Adjemian J, Steiner CA, Prevots DR. Epidemiology of hospitalizations associated with invasive candidiasis, United States, 2002–2012. Emerg Infect Dis 2016;23:7–13. https://doi.org/10.3201/eid2301.161198
50. 50. See I, Wesson P, Gualandi N, et al. Socioeconomic factors explain racial disparities in invasive community-associated methicillin-resistant Staphylococcus aureus disease rates. Clin Infect Dis 2017;64:597–604. https://doi.org/10.1093/cid/ciw808
51. 51. Wong MD, Shapiro MF, Boscardin WJ, Ettner SL. Contribution of major diseases to disparities in mortality. N Engl J Med 2002;347:1585–92. https://doi.org/10.1056/NEJMsa012979
52. 52. Fanfair RN. Blacks at twofold increased risk for candidemia infections. Infectious Disease News, Science Daily. Rockville, MD; 2011. https://www.healio. com/infectious-disease/vaccine-preventable-diseases/news/print/infectiousdisease- news/%7Bf5afa7f7-85d7-4be9-9700-d02625b9c821%7D/ blacks-at-twofold-increased-risk-for-candidemia-infections
53. 53. Alp S, Arikan-Akdagli S, Gulmez D, Ascioglu S, Uzun O, Akova M. Epidemiology of candidaemia in a tertiary care university hospital: 10-year experience with 381 candidaemia episodes between 2001 and 2010. Mycoses 2015;58:498–505. https://doi.org/10.1111/myc.12349
54. 54. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992;15:414–21. https://doi.org/10.1093/clind/15.3.414
55. 55. Lansky A, Finlayson T, Johnson C, et al. Estimating the number of persons who inject drugs in the United States by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS One 2014;9:e97596. https://doi.org/10.1371/journal.pone.0097596
56. 56. Poowanawittayakom N, Dutta A, Stock S, Touray S, Ellison RT 3rd, Levitz SM. Reemergence of intravenous drug use as risk factor for candidemia, Massachusetts, USA. Emerg Infect Dis 2018;24:631–7. https://doi.org/10.3201/eid2404.171807
57. 57. Vivolo-Kantor AM, Seth P, Gladden RM, et al. Trends in emergency department visits for suspected opioid overdoses—United States, July 2016–September 2017. MMWR Morb Mortal Wkly Rep 2018;67:279–85. https://doi.org/10.15585/mmwr.mm6709e1
58. 58. Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016. MMWR Morb Mortal Wkly Rep 2018;67:349–58. https://doi.org/10.15585/ mmwr.mm6712a1
59. 59. Jackson KA, Bohm MK, Brooks JT, et al. Invasive methicillin-resistant Staphylococcus aureus infections among persons who inject drugs—six sites, 2005–2016. MMWR Morb Mortal Wkly Rep 2018;67:625–8. https://doi.org/10.15585/mmwr.mm6722a2
60. 60. CDC. Antibiotic resistance threats in the United States. Washington, DC: US Department of Health and Human Services; 2013. https:// www.cdc.gov/drugresistance/threat-report-2013/index.html
61. 61. Perlin DS. Echinocandin resistance in Candida. Clin Infect Dis 2015;61(Suppl 6):S612–7. https://doi.org/10.1093/cid/civ791
62. 62. Vallabhaneni S, Sapiano M, Weiner LM, Lockhart SR, Magill S. Antifungal susceptibility testing practices at acute care hospitals enrolled in the National Healthcare Safety Network, United States, 2011–2015. Open Forum Infect Dis 2017;4:ofx175. https://doi.org/10.1093/ofid/ofx175
63. 63. CDC. Lab capacity: Antibiotic Resistance Laboratory Network (AR Lab Network) [Internet]. Atlanta, GA: US Department of Health and Human Services, CDC; 2018. https://www.cdc.gov/drugresistance/ solutions-initiative/ar-lab-networks.html
64. 64. Pappas PG, Kauffman CA, Andes D, et al; Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503–35. https://doi.org/10.1086/596757
65. 65. Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity: a review. J Chemother 2000;12:463–70. https://doi.org/10.1179/joc.2000.12.6.463
66. 66. Chow NA, Gade L, Tsay SV, et al; US Candida auris Investigation Team. Multiple introductions and subsequent transmission of multidrug-resistant Candida auris in the USA: a molecular epidemiological survey. Lancet Infect Dis 2018;18:1377–84. https://doi.org/10.1016/S1473-3099(18)30597-8
67. 67. Lockhart SR, Etienne KA, Vallabhaneni S, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis 2017;64:134–40. https://doi.org/10.1093/cid/ciw691
68. 68. Welsh RM, Bentz ML, Shams A, et al. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface. J Clin Microbiol 2017;55:2996–3005. https://doi.org/10.1128/JCM.00921-17
69. 69. Vallabhaneni S, Kallen A, Tsay S, et al. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrugresistant fungus—United States, May 2013–August 2016. MMWR Morb Mortal Wkly Rep 2016;65:1234–7.
70. 70. Ramos R, Caceres DH, Perez M, et al; Red Nacional de Vigilancia Epidemiologica en Microbiologia Clinica. Emerging multidrug-resistant Candida duobushaemulonii infections in Panama hospitals: importance of laboratory surveillance and accurate identification. J Clin Microbiol 2018;56:e00371–18.
71. 71. Escandón P, Cáceres DH, Espinosa-Bode A, et al. Notes from the field: surveillance for Candida auris—Colombia, September 2016–May 2017. MMWR Morb Mortal Wkly Rep 2018;67:459–60.